Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Open-label, Safety Rollover Trial of Obrixtamig in Patients With Different Tumours

NCT07929051 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07929051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Open-label, Safety Rollover Trial of Obrixtamig in Patients With Different Tumours
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Not yet recruiting
Start date
March 4, 2027
Completion date
July 3, 2028
Enrollment
68 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer

Arms

As registered; 1 arm.

  • Rollover arm ExperimentalAtezolizumab, Ezabenlimab, Obrixtamig, Tocilizumab, Topotecan

    Patients who have previously received treatment with obrixtamig in another Boehringer Ingelheim-sponsored clinical trial (referred to as the 'parent trial') will be enrolled in this rollover study.

    Treatment schedule and doses in the parent study will be continued in the rollover study.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Occurrence of treatment-emergent adverse events ( AEs) during the on-treatment period. Up to 36 months

Lead sponsor's other trials

Boehringer Ingelheim, most recent start first.